| Literature DB >> 29224780 |
Norman Sachs1, Joep de Ligt2, Oded Kopper3, Ewa Gogola4, Gergana Bounova5, Fleur Weeber6, Anjali Vanita Balgobind7, Karin Wind8, Ana Gracanin8, Harry Begthel8, Jeroen Korving8, Ruben van Boxtel2, Alexandra Alves Duarte4, Daphne Lelieveld9, Arne van Hoeck2, Robert Frans Ernst2, Francis Blokzijl2, Isaac Johannes Nijman2, Marlous Hoogstraat10, Marieke van de Ven11, David Anthony Egan9, Vittoria Zinzalla12, Jurgen Moll12, Sylvia Fernandez Boj13, Emile Eugene Voest6, Lodewyk Wessels14, Paul Joannes van Diest15, Sven Rottenberg16, Robert Gerhardus Jacob Vries13, Edwin Cuppen2, Hans Clevers17.
Abstract
Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging. BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response. This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.Entities:
Keywords: basal; biobank; breast cancer; luminal; organoids; precision medicine; triple negative
Mesh:
Substances:
Year: 2017 PMID: 29224780 DOI: 10.1016/j.cell.2017.11.010
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582